Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 7/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615990 | 0.76 | ALDH1A1 (0.38) | GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL918324 | 0.75 | DCUN1D1 (0.47) | GAAKDM4EMEN1USP2HTT | |
| SCHEMBL27761643 | 0.73 | GAA (0.44) | GAAKDM4EMEN1USP2HTT | |
| SCHEMBL931845 | 0.72 | HSP90AA1 (0.43) | GAAKDM4EMEN1HTTKMT2A | |
| SCHEMBL5333176 | 0.72 | HTR7 (0.55) | — | |
| Hydrochloric Acid SCHEMBL27741149 | 0.71 | GAA (0.43) | GAAKDM4EUSP2HTTALDH1A1 | |
| SCHEMBL28340371 | 0.71 | IDO1 (0.47) | GAAKDM4EMEN1USP2KMT2A | |
| SCHEMBL13407536 | 0.71 | NOTUM (0.36) | ALDH1A1 | |
| Methylbiphenyl Tetrazole SCHEMBL29457258 | 0.70 | NR1H2 (0.39) | KDM4EMEN1TP53KMT2AALDH1A1 | |
| Methylbiphenyl Tetrazole SCHEMBL1774035 | 0.70 | NR1H2 (0.39) | KDM4EMEN1TP53KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917203-B1 | METHOD FOR IDENTIFYING MYC INHIBITORS | DANA FARBER CANCER INST INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2014071247-A1 | PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | MYC, MYCBP, YAP1 | GAA 879/4885KDM4E 1673/4885MEN1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.